881185-98-4

Basic information

• Product Name: Ethanone, 1-[2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-
• CAS NO: 881185-98-4
• Molecular Formula: C15H21BO4
• Molecular Weight: 276.14
• Mol File: 881185-98-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Ethanone, 1-[2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-[2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-(881185-98-4)
• EPA Substance Registry System: Ethanone, 1-[2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-(881185-98-4)

Safety Data

• Hazardous Substances Data: 881185-98-4(Hazardous Substances Data)

Upstream product

• 89368-12-7 1-[4-bromo-2-(methyloxy)phenyl]ethanone 
• 638214-65-0 1-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethan-1-one 
• 579-74-8 2-Methoxyacetophenone 
• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 
• 1450-75-5 5-Bromo-2-hydroxyacetophenone 
• 1927-95-3 4-bromophenyl acetate 
• 106-41-2 4-bromo-phenol 
• 16740-73-1 5-bromo-2-methoxyacetophenone 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 579-74-8 2-Methoxyacetophenone 
• 31405-60-4 1-(5-hydroxy-2-methoxyphenyl)ethan-1-one 

Relevant articles and documents

Formylchromone derivatives as a novel class of protein tyrosine phosphatase 1B inhibitors

Formylchromone inhibits a human protein tyrosine phosphatase PTP1B with a IC50 value of 73 μM. The chemical reactivity of formylchromone was adjusted by substitution at various positions of the formylchromone skeleton. In an initial assessment of the structure-activity relationship, the most potent inhibitor showed an IC50 of 4.3 μM against PTP1B and strong or medium selectivity against other human PTPases, LAR and TC-PTP. This compound, however, was not selective against microbial PTPases, YPTP1 and YOP. The potency and selectivity of the formylchromone derivatives expecting further improvements provides a novel pharmacophore for the design of drugs for the treatmenrt of type 2 diabetes and obesity.